Well I have picked up the link and pasted it for you, but is...

Well I have picked up the link and pasted it for you, but is more impressive if you read it on the official (Hovione) page.




print version

Nº21 | March | 2007


TWINCAPS – A NEW TECHNOLOGY

For flu medicines

Hovione has just signed an important technology license agreement with Sankyo and Biota - Sankyo, after its fusion with Dai-Ichi, will be the second largest Japanese pharmaceutical company, and Biota is an Australian laboratory specialized in anti-viral drugs. Hovione is developing for these partners, innovative technologies in the fields of formulation and pulmonary inhalation The medicine which Hovione´s technology made possible treats pulmonary diseases such as flu and will be administered through a new lung inhaler also developed specifically for this purpose by Hovione.

Congratulations!


There are a couple of reasons why I think it hasn,t been released well 3 to be precise..............Hovione seem to be proud to put it on one of there Company Heading pages...............A good advertisement for Hovione, since they came up with the Twin Caps Inhaler, are the makers of the Bulk Lani formula and the manufacturer and it seems the Licensee of the product for Sankyo and Biota.

Reason 1. Sanyko are not ready for Lani to be released into the Japan/Asia market just yet, maybe some paperwork to be finalised.

Reason 2. Biota have asked Sankyo to hold off releasing it until things are settled with GSK IF they are in the middle of negotiations?

Reason 3. The 3 companies need to simulate the announcement, which is beneficial to all 3 companies, maybe Hovione have not geared up for production yet?

Just my thoughts, this is a large market as big as the US Seasonal Flu market, and the best part is Biota as partner with Sankyo share in 50% not a measley 6% from Relenza...........(Maybe the percentage will be raised if there is a settlement)?????????????

Cheers dma